Last reviewed · How we verify
HSK39297 200mgQD — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
HSK39297 200mgQD (HSK39297 200mgQD) — Haisco Pharmaceutical Group Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| HSK39297 200mgQD TARGET | HSK39297 200mgQD | Haisco Pharmaceutical Group Co., Ltd. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- HSK39297 200mgQD CI watch — RSS
- HSK39297 200mgQD CI watch — Atom
- HSK39297 200mgQD CI watch — JSON
- HSK39297 200mgQD alone — RSS
Cite this brief
Drug Landscape (2026). HSK39297 200mgQD — Competitive Intelligence Brief. https://druglandscape.com/ci/hsk39297-200mgqd. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab